Statin use and exacerbations in individuals with chronic obstructive pulmonary disease

Thorax

Volumn 70, Issue 1, 2015, Pages 33-40

  Ingebrigtsen, Truls S ^a,b,c   Marott, Jacob L ^b   Nordestgaard, Børge G ^b,c   Lange, Peter ^b,c,d   Hallas, Jesper ^e   Vestbo, Jørgen ^c,f  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b FREDERIKSBERG HOSPITAL   (Denmark)

^c Mental Health Services CPH   (Denmark)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

^e UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^f UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BRONCHODILATING AGENT; C REACTIVE PROTEIN; CORTICOSTEROID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGE; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CASE CONTROL STUDY; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFECT; DRUG USE; FEMALE; FOLLOW UP; GENDER; HOSPITAL ADMISSION; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; RISK ASSESSMENT; RISK REDUCTION; SMOKING; CLINICAL TRIAL; DISEASE COURSE; MULTICENTER STUDY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RETROSPECTIVE STUDY; TIME; TREATMENT OUTCOME;

AGED; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RECURRENCE; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84919772728     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thoraxjnl-2014-205795     Document Type: Article

References (42)

1. Lopez AD, Shibuya K, Rao C, et al. Chronic obstructive pulmonary disease: current burden and future projections. Eur Respir J 2006;27:397-412.
2. Pauwels RA, Rabe KF. Burden and clinical features of chronic obstructive pulmonary disease (COPD). Lancet 2004;364:613-20.
3. Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010;363:1128-38.
4. Vestbo J, Hurd SS, Agusti AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013;187:347-65.
5. Gan WQ, Man SF, Senthilselvan A, et al. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 2004;59:574-80.
6. Sinden NJ, Stockley RA. Systemic inflammation and comorbidity in COPD: a result of 'overspill ' of in flammatory mediators from the lungs? Review of the evidence. Thorax 2010;65:930-6.
7. Young RP, Hopkins R, Eaton TE. Potential benefi ts of statins on morbidity and mortality in chronic obstructive pulmonary disease: a review of the evidence. Postgrad Med J 2009;85:414-21.
8. Wang CY, Liu PY, Liao JK. Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends Mol Med 2008;14:37-44.
9. Davignon J. Pleiotropic effects of pitavastatin. Br J Clin Pharmacol 2012;73:518-35.
10. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-207.
11. Ridker PM, Danielson E, Fonseca FA, et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 2009;373:1175-82.
12. Wang MT, Lo YW, Tsai CL, et al . Statin use and risk of COPD exacerbation requiring hospitalization. Am J Med 2013;126:598-606.e2.
13. Janda S, Park K, FitzGerald JM, et al. Statins in COPD: a systematic review. Chest 2009;136:734-43.
14. Criner GJ, Connett JE, Aaron SD, et al. Simvastatin for the Prevention of Exacerbations in Moderate-to-Severe COPD. N Engl J Med 2014;370:2201-10.
15. Lange P, Marott JL, Vestbo J, et al. Prediction of the clinical course of chronic obstructive pulmonary disease, using the new GOLD classification: a study of the general population. Am J Respir Crit Care Med 2012;186:975-81.
16. Ingebrigtsen TS, Marott JL, Vestbo J, et al. Characteristics of undertreatment in COPD in the general population. Chest 2013;144:1811 -18.
17. Lynge E, Sandegaard JL, Rebolj M. The Danish National Patient Register. Scand J Public Health 2011;39(7 Suppl):30-3.
18. Thomsen M, Ingebrigtsen TS, Marott JL, et al. Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease. JAMA 2013;309:2353-61.
19. Kildemoes HW, Sørensen HT, Hallas J. The Danish National Prescription Registry. Scand J Public Health 2011;39:38-41.
20. WHO Collaborating Centre for Drug Statistics Methodology. [cited 9 August 2014]. http://www.whocc.no
21. Richardson DB. An incidence density sampling program for nested case-control analyses. Occup Environ Med 2004;61:e59.
22. D'Hoore W, Bouckaert A, Tilquin C. Practical considerations on the use of the Charlson comorbidity index with administrative data bases. J Clin Epidemiol 1996;49:1429-33.
23. Strom B. Pharmacoepidemiology. 4th edn. Chichester, UK: John Wiley & Sons, 2005.
24. Essebag V, Platt RW, Abrahamowicz M, et al. Comparison of nested case-control and survival analysis methodologies for analysis of time-dependent exposure. BMC Med Res Methodol 2005;5:5.
25. Essebag V, Genest J Jr, Suissa S, et al. The nested case-control study in cardiology. Am Heart J 2003;146:581-90.
26. Lu Y, Hajifathalian K, Ezzati M, et al.; The Global Burden of Metabolic Risk Factors for Chronic Diseases Collaboration (BMI mediated effects). Metabolic mediators of the effects of body-mass index, overweight, and obesity on coronary heart disease and stroke: a pooled analysis of 97 prospective cohorts with 1.8 million participants. Lancet 2014;383:970-83.
27. The Comprehensive R Archive Network. [cited 9 August 2014]. http://cran.r-project. org/
28. Crawley M. The R book. Imperial College London at Silwood Park. London, UK: John Wiley & Sons, Ltd., 2007.
29. Lange P, Marott JL, Vestbo J, et al . Socioeconomic status and prognosis of COPD in Denmark. COPD 2014;11:431-7.
30. Truelsen T, Gronbaek M, Schnohr P, et al. Intake of beer, wine, and spirits and risk of stroke : the copenhagen city heart study. Stroke 1998;29:2467-72.
31. Wium-Andersen MK, Orsted DD, Nielsen SF, et al. Elevated C-reactive protein levels, psychological distress, and depression in 73, 131 individuals. JAMA Psychiatry 2013;70:176-84.
32. DiCiccio TJ, Efron B. Bootstrap confidence intervals. Stat Sci 1996;11:189-228.
33. Lahousse L, Loth DW, Joos GF, et al. Statins, systemic inflammation and risk of death in COPD: the Rotterdam study. Pulm Pharmacol Ther 2013;26:212-17.
34. Blamoun AI, Batty GN, DeBari VA, et al. Statins may reduce episodes of exacerbation and the requirement for intubation in patients with COPD: evidence from a retrospective cohort study. Int J Clin Pract 2008;62:1373-8.
35. Huang CC, Chan WL, Chen YC, et al . Statin use and hospitalization in patients with chronic obstructive pulmonary disease: a nationwide population-based cohort study in Taiwan. Clin Ther 2011;33:1365-70.
36. Sode BF, Dahl M, Nordestgaard BG. Myocardial infarction and other co-morbidities in patients with chronic obstructive pulmonary disease: a Danish nationwide study of 7.4 million individuals. Eur Heart J 2011;32:2365-75.
37. Sin DD, Man SF. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 2003;107:1514-19.
38. Garcia-Aymerich J, Gomez FP, Benet M, et al. Identification and prospective validation of clinically relevant chronic obstructive pulmonary disease (COPD) subtypes. Thorax 2011;66:430-7.
39. Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 2000;342:1887-92.
40. Hannan EL. Randomized clinical trials and observational studies: guidelines for assessing respective strengths and limitations. JACC Cardiovasc Interv 2008;1:211-17.
41. Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008;359:1543-54.
42. Calverley P, Pauwels R, Vestbo J, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003;361:449-56.